AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 19919581 — intervention group
Group type: EXPERIMENTAL
Intervention: Lidocaine 2 mg/kg i.v., followed by 2 mg/kg/h i.v.
Number of subjects: 120
Study 19919581 — intervention group
Group type: EXPERIMENTAL
Intervention: Magnesium sulfate 50 mg/kg i.v., followed by 25 mg/kg/h i.v.
Number of subjects: 120
Study 19919581 — intervention group
Group type: COMPARATOR
Intervention: Saline i.v. (control group)
Number of subjects: 120
Study 17070701 — intervention group
Group type: EXPERIMENTAL
Intervention: Biofeedback + exercise
Number of subjects: 26
Study 17070701 — intervention group
Group type: COMPARATOR
Intervention: Exercise
Number of subjects: 26
Study 15994216 — intervention group
Group type: EXPERIMENTAL
Intervention: Antiviral treatment with interferon alpha-2b and ribavirin
Number of subjects: 0
Study 15994216 — intervention group
Group type: EXPERIMENTAL
Intervention: Peginterferon alpha-2b and ribavirin
Number of subjects: 0
Study 15994216 — intervention group
Group type: COMPARATOR
Intervention: No treatment (control)
Number of subjects: 0
Study 14530550 — intervention group
Group type: EXPERIMENTAL
Intervention: Random urine calcium/creatinine ratio (UCa/Cr)
Number of subjects: 324
Study 10380385 — intervention group
Group type: EXPERIMENTAL
Intervention: Standardized home-care nursing intervention
Number of subjects: 161
Study 10380385 — intervention group
Group type: COMPARATOR
Intervention: Control group (no home-care intervention)
Number of subjects: 161
Study 9055329 — intervention group
Group type: EXPERIMENTAL
Intervention: Dorsal rootlet stimulation during partial dorsal rhizotomy (PDR)
Number of subjects: 6
Study 1676776 — intervention group
Group type: EXPERIMENTAL
Intervention: Ozone followed by allergen
Number of subjects: 7
Study 1676776 — intervention group
Group type: COMPARATOR
Intervention: Air followed by allergen
Number of subjects: 7
Study 1676776 — intervention group
Group type: COMPARATOR
Intervention: Air breathing followed by inhalation of allergen diluent (placebo)
Number of subjects: 7
Study 1676776 — intervention group
Group type: COMPARATOR
Intervention: Ozone followed by inhalation of allergen diluent
Number of subjects: 7
Study 6634352 — intervention group
Group type: EXPERIMENTAL
Intervention: Olfactory aversion therapy
Number of subjects: 42
Study 6634352 — intervention group
Group type: COMPARATOR
Intervention: Attention placebo control
Number of subjects: 42
Study 6634352 — intervention group
Group type: COMPARATOR
Intervention: No-contact control
Number of subjects: 42
Study 31589290 — intervention group
Group type: EXPERIMENTAL
Intervention: Liraglutide
Number of subjects: 3154
Study 31589290 — intervention group
Group type: EXPERIMENTAL
Intervention: Exendin-4
Number of subjects: 3154
Study 31589290 — intervention group
Group type: COMPARATOR
Intervention: GLP-1RA exposure
Number of subjects: 3154
Study 29433340 — intervention group
Group type: EXPERIMENTAL
Intervention: Rumination
Number of subjects: 54
Study 29433340 — intervention group
Group type: EXPERIMENTAL
Intervention: Worry
Number of subjects: 54
Study 29433340 — intervention group
Group type: COMPARATOR
Intervention: Distraction
Number of subjects: 54
Study 27192132 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 minutes of 15.8°C cold water immersion (CWI)
Number of subjects: 16
Study 27192132 — intervention group
Group type: EXPERIMENTAL
Intervention: Ingestion of 6.8 g/kg‐1 of slushie with application of iced towels to the legs, torso and back/arms (ST)
Number of subjects: 16
Study 27192132 — intervention group
Group type: COMPARATOR
Intervention: Ingestion of 6.8 g/kg‐1 of room temperature (22.3°C) sports drink (CON)
Number of subjects: 16
Study 24467770 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous quality improvement (CQI) intervention
Number of subjects: 8
Study 24467770 — intervention group
Group type: COMPARATOR
Intervention: Control condition (initially assigned)
Number of subjects: 8
Study 22688312 — intervention group
Group type: EXPERIMENTAL
Intervention: Clopidogrel 300 mg loading dose followed by 75 mg maintenance dose
Number of subjects: 1003
Study 22688312 — intervention group
Group type: COMPARATOR
Intervention: Ticlopidine 100 mg twice daily
Number of subjects: 1003
Study 20863927 — intervention group
Group type: EXPERIMENTAL
Intervention: Generic Sevoflurane
Number of subjects: 64
Study 20863927 — intervention group
Group type: COMPARATOR
Intervention: Sevorane™
Number of subjects: 64
Study 18753700 — intervention group
Group type: EXPERIMENTAL
Intervention: Intracoronary bolus tirofiban
Number of subjects: 118
Study 15842521 — intervention group
Group type: EXPERIMENTAL
Intervention: Metformin
Number of subjects: 183
Study 12684609 — intervention group
Group type: EXPERIMENTAL
Intervention: Amisulpride (400-800 mg/day)
Number of subjects: 48
Study 12684609 — intervention group
Group type: COMPARATOR
Intervention: Risperidone (4-8 mg/day)
Number of subjects: 48
Study 12684609 — intervention group
Group type: EXPERIMENTAL
Intervention: Amisulpride
Number of subjects: 48
Study 12684609 — intervention group
Group type: COMPARATOR
Intervention: Risperidone
Number of subjects: 48
Study 10998481 — intervention group
Group type: EXPERIMENTAL
Intervention: Atorvastatin (10 mg/day)
Number of subjects: 18
Study 10998481 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin C
Number of subjects: 18
Study 10998481 — intervention group
Group type: COMPARATOR
Intervention: Control group (12 normal volunteers, 7 men and 5 women, aged 20-45 years)
Number of subjects: 18
Study 8831181 — intervention group
Group type: EXPERIMENTAL
Intervention: Nifedipine SR 20 mg b.i.d.
Number of subjects: 20
Study 8831181 — intervention group
Group type: EXPERIMENTAL
Intervention: Metoprolol (OROS) 14/190 mg o.d.
Number of subjects: 20
Study 8831181 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of metoprolol and nifedipine
Number of subjects: 20
Study 8831181 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 1336463 — intervention group
Group type: EXPERIMENTAL
Intervention: lisinopril (20 mg/40 mg o.d.)
Number of subjects: 49
Study 1336463 — intervention group
Group type: EXPERIMENTAL
Intervention: atenolol (50 mg/100 mg o.d.)
Number of subjects: 49
Study 1336463 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 49
Study 4016825 — intervention group
Group type: EXPERIMENTAL
Intervention: Naloxone (0.8 mg bolus, intravenous)
Number of subjects: 5
Study 31060838 — intervention group
Group type: COMPARATOR
Intervention: Standard enteral nutrition (14.1 g/100 mL carbohydrate)
Number of subjects: 41
Study 31060838 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention enteral nutrition (7.4 g/100 mL carbohydrate)
Number of subjects: 41
Study 29706458 — intervention group
Group type: EXPERIMENTAL
Intervention: Radical prostatectomy
Number of subjects: 220
Study 29706458 — intervention group
Group type: EXPERIMENTAL
Intervention: External radiotherapy
Number of subjects: 220
Study 29706458 — intervention group
Group type: EXPERIMENTAL
Intervention: Active surveillance
Number of subjects: 220
Study 27081039 — intervention group
Group type: EXPERIMENTAL
Intervention: Prophylactic donor lymphocyte infusion (DLI)
Number of subjects: 153
Study 27081039 — intervention group
Group type: COMPARATOR
Intervention: Non-DLI
Number of subjects: 153
Study 24582316 — intervention group
Group type: EXPERIMENTAL
Intervention: GSK679586 (10 mg/kg, once-monthly intravenous infusions)
Number of subjects: 198
Study 24582316 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 198
Study 24582316 — intervention group
Group type: EXPERIMENTAL
Intervention: GSK679586
Number of subjects: 198
Study 22158915 — intervention group
Group type: EXPERIMENTAL
Intervention: Pseudoephedrine (PSE) 2.5 mg/kg
Number of subjects: 15
Study 22158915 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15
Study 22158915 — intervention group
Group type: EXPERIMENTAL
Intervention: Pseudoephedrine (PSE)
Number of subjects: 15
Study 19880909 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled mannitol 420 mg bid for 2 weeks
Number of subjects: 28
Study 19880909 — intervention group
Group type: COMPARATOR
Intervention: Placebo treatment
Number of subjects: 28
Study 17972485 — intervention group
Group type: EXPERIMENTAL
Intervention: Upper position with shaded parallelepipeds whose upper/bottom faces were lighter than their side faces
Number of subjects: 0
Study 17972485 — intervention group
Group type: EXPERIMENTAL
Intervention: Upper position with shaded objects whose upper/bottom faces were darker than their side faces
Number of subjects: 0
Study 17972485 — intervention group
Group type: EXPERIMENTAL
Intervention: Lower position with shaded parallelepipeds whose upper/bottom faces were lighter than their side faces
Number of subjects: 0
Study 17972485 — intervention group
Group type: EXPERIMENTAL
Intervention: Lower position with shaded objects whose upper/bottom faces were darker than their side faces
Number of subjects: 0
Study 17972485 — intervention group
Group type: COMPARATOR
Intervention: Upper position
Number of subjects: 0
Study 15723893 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive intervention (information and physical exercise)
Number of subjects: 152
Study 15723893 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 152
Study 10831487 — intervention group
Group type: EXPERIMENTAL
Intervention: Sertraline
Number of subjects: 302
Study 10831487 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 302
Study 9332920 — intervention group
Group type: EXPERIMENTAL
Intervention: Blood cardioplegia and single aortic cross‐clamp technique (Group II)
Number of subjects: 100
Study 9332920 — intervention group
Group type: COMPARATOR
Intervention: Crystalloid cardioplegia and conventional partial occluding clamp technique (Group I)
Number of subjects: 100
Study 8374246 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous zinc supplementation for 2 months
Number of subjects: 65
Study 3946944 — intervention group
Group type: EXPERIMENTAL
Intervention: Ophthalmic timolol (0.5%)
Number of subjects: 20
Study 3946944 — intervention group
Group type: COMPARATOR
Intervention: Placebo (artificial tears)
Number of subjects: 20
Study 29445852 — intervention group
Group type: EXPERIMENTAL
Intervention: 12-hour patient educational program
Number of subjects: 168
Study 29445852 — intervention group
Group type: COMPARATOR
Intervention: Waiting control group
Number of subjects: 168
Study 26409199 — intervention group
Group type: EXPERIMENTAL
Intervention: Supportive footwear and stretching intervention
Number of subjects: 77
Study 24136677 — intervention group
Group type: EXPERIMENTAL
Intervention: Minimal access microdiscectomy (MAMD)
Number of subjects: 60
Study 24136677 — intervention group
Group type: COMPARATOR
Intervention: Standard open microdiscectomy (SOMD)
Number of subjects: 60
Study 24136677 — intervention group
Group type: EXPERIMENTAL
Intervention: Both MAMD and SOMD
Number of subjects: 60
Study 21440501 — intervention group
Group type: EXPERIMENTAL
Intervention: AMI patients
Number of subjects: 275
Study 21440501 — intervention group
Group type: EXPERIMENTAL
Intervention: CABGS patients
Number of subjects: 275
Study 21440501 — intervention group
Group type: EXPERIMENTAL
Intervention: PCI patients
Number of subjects: 275
Study 21440501 — intervention group
Group type: EXPERIMENTAL
Intervention: All patients
Number of subjects: 275
Study 18501861 — intervention group
Group type: EXPERIMENTAL
Intervention: Prenatal drug exposure (PDE) group
Number of subjects: 173
Study 18501861 — intervention group
Group type: COMPARATOR
Intervention: Non-drug-exposed children (control group)
Number of subjects: 173
Study 18501861 — intervention group
Group type: EXPERIMENTAL
Intervention: Gender comparison (males vs females)
Number of subjects: 173
Study 16750458 — intervention group
Group type: EXPERIMENTAL
Intervention: Fosinopril 20 mg
Number of subjects: 864
Study 16750458 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 864
Study 15804071 — intervention group
Group type: EXPERIMENTAL
Intervention: Sibutramine 10 mg/day for 12 weeks
Number of subjects: 70
Study 15804071 — intervention group
Group type: COMPARATOR
Intervention: Placebo tablet/day for 12 weeks
Number of subjects: 70
Study 15804071 — intervention group
Group type: COMPARATOR
Intervention: Normal control (healthy adults with BMI < 23 kg/m2)
Number of subjects: 70
Study 10880268 — intervention group
Group type: EXPERIMENTAL
Intervention: General anaesthesia
Number of subjects: 12
Study 10880268 — intervention group
Group type: COMPARATOR
Intervention: Regional spinal/epidural anaesthesia
Number of subjects: 12
Study 9195320 — intervention group
Group type: EXPERIMENTAL
Intervention: Femoral component with a distal centralizing device
Number of subjects: 60
Study 9195320 — intervention group
Group type: COMPARATOR
Intervention: Femoral component without a distal centralizing device
Number of subjects: 60
Study 1555691 — intervention group
Group type: EXPERIMENTAL
Intervention: hMG alone for ovarian stimulation (group A, n = 81)
Number of subjects: 308
Study 1555691 — intervention group
Group type: EXPERIMENTAL
Intervention: Clomiphene citrate and hMG (group B, n = 77)
Number of subjects: 308
Study 1555691 — intervention group
Group type: EXPERIMENTAL
Intervention: 3-day ultrashort course of GnRH-a and hMG (group C, n = 74)
Number of subjects: 308
Study 1555691 — intervention group
Group type: EXPERIMENTAL
Intervention: Pituitary desensitization with GnRH-a followed by hMG (group D, n = 76)
Number of subjects: 308
Study 1555691 — intervention group
Group type: COMPARATOR
Intervention: All groups (A, B, C, D)
Number of subjects: 308
Study 3080283 — intervention group
Group type: EXPERIMENTAL
Intervention: Misoprostol 200 micrograms
Number of subjects: 8
Study 3080283 — intervention group
Group type: EXPERIMENTAL
Intervention: Misoprostol 400 micrograms
Number of subjects: 8
Study 3080283 — intervention group
Group type: EXPERIMENTAL
Intervention: Misoprostol 800 micrograms
Number of subjects: 8
Study 3080283 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study 30324545 — intervention group
Group type: EXPERIMENTAL
Intervention: Remifentanil-propofol
Number of subjects: 56
Study 30324545 — intervention group
Group type: COMPARATOR
Intervention: Propofol alone
Number of subjects: 56
Study 27138022 — intervention group
Group type: EXPERIMENTAL
Intervention: Single dose of VGX-1027 (1-800 mg)
Number of subjects: 0
Study 27138022 — intervention group
Group type: EXPERIMENTAL
Intervention: Multiple doses of VGX-1027 (40-400 mg)
Number of subjects: 0
Study 27138022 — intervention group
Group type: EXPERIMENTAL
Intervention: Pharmacokinetics of VGX-1027
Number of subjects: 0
Study 27138022 — intervention group
Group type: EXPERIMENTAL
Intervention: Single-dose study
Number of subjects: 0
Study 27138022 — intervention group
Group type: EXPERIMENTAL
Intervention: Multiple-dose study
Number of subjects: 0
Study 27138022 — intervention group
Group type: EXPERIMENTAL
Intervention: Drug accumulation
Number of subjects: 0
Study 27138022 — intervention group
Group type: EXPERIMENTAL
Intervention: Excretion of VGX-1027
Number of subjects: 0
Study 24485998 — intervention group
Group type: EXPERIMENTAL
Intervention: Retroperitoneoscopic pyeloplasty
Number of subjects: 60
Study 24485998 — intervention group
Group type: COMPARATOR
Intervention: Open pyeloplasty with minimal incision
Number of subjects: 60
Study 22572058 — intervention group
Group type: EXPERIMENTAL
Intervention: Brief alcohol intervention (BAI) offered to trial participants
Number of subjects: 0
Study 22572058 — intervention group
Group type: COMPARATOR
Intervention: Brief alcohol intervention (BAI) offered to volunteers
Number of subjects: 0
Study 20502265 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgical resection of pulmonary metastases
Number of subjects: 0
Study 20502265 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study 18507669 — intervention group
Group type: EXPERIMENTAL
Intervention: Recurrence quantification analysis (RQA) measures in DM group
Number of subjects: 34
Study 18507669 — intervention group
Group type: EXPERIMENTAL
Intervention: Trapping time measure in DM group
Number of subjects: 34
Study 20216023 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasound guidance for truncal blocks
Number of subjects: 0
Study 20216023 — intervention group
Group type: COMPARATOR
Intervention: Traditional techniques for truncal blocks
Number of subjects: 0
Study 16360059 — intervention group
Group type: EXPERIMENTAL
Intervention: BDOO pacing
Number of subjects: 19
Study 16360059 — intervention group
Group type: COMPARATOR
Intervention: CDOO pacing
Number of subjects: 19
Study 16360059 — intervention group
Group type: COMPARATOR
Intervention: AOO pacing
Number of subjects: 19
Study 12019482 — intervention group
Group type: EXPERIMENTAL
Intervention: Auricularum powder (dexamethasone 10 mg, oxytetracycline HCl 90,000 U, polymyxin B Sulfate 100,000 U, nystatin 1,000,000 U)
Number of subjects: 120
Study 12019482 — intervention group
Group type: EXPERIMENTAL
Intervention: Ciprofloxacin drops (Ciloxan)
Number of subjects: 120
Study 12019482 — intervention group
Group type: EXPERIMENTAL
Intervention: Tobramycin drops (Tobrex)
Number of subjects: 120
Study 12019482 — intervention group
Group type: EXPERIMENTAL
Intervention: All treatments (Auricularum powder, Ciprofloxacin, Tobramycin)
Number of subjects: 120
Study 9786607 — intervention group
Group type: EXPERIMENTAL
Intervention: Cilnidipine (5 to 20 mg once daily)
Number of subjects: 10
Study 9786607 — intervention group
Group type: COMPARATOR
Intervention: Nisoldipine (5 to 20 mg once daily)
Number of subjects: 10
Study 9786607 — intervention group
Group type: EXPERIMENTAL
Intervention: Cilnidipine
Number of subjects: 10
Study 9786607 — intervention group
Group type: COMPARATOR
Intervention: Nisoldipine
Number of subjects: 10
Study 7941918 — intervention group
Group type: EXPERIMENTAL
Intervention: Diltiazem 300 mg od
Number of subjects: 230
Study 7941918 — intervention group
Group type: EXPERIMENTAL
Intervention: Nifedipine 20 mg bd
Number of subjects: 230
Study 7941918 — intervention group
Group type: EXPERIMENTAL
Intervention: Bendrofluazide 5 mg od
Number of subjects: 230
Study 2960271 — intervention group
Group type: EXPERIMENTAL
Intervention: Placebo transdermal therapeutic system
Number of subjects: 25
Study 2960271 — intervention group
Group type: EXPERIMENTAL
Intervention: Silver-patch test
Number of subjects: 25
Study 29145543 — intervention group
Group type: EXPERIMENTAL
Intervention: Ipilimumab, 10 mg/kg, every 21 days for 4 cycles followed by 4 cycles of maintenance therapy every 12 weeks
Number of subjects: 42
Study 29145543 — intervention group
Group type: EXPERIMENTAL
Intervention: Ipilimumab, 3 mg/kg, every 21 days for 4 cycles (run-in safety cohort)
Number of subjects: 42
Study 29145543 — intervention group
Group type: EXPERIMENTAL
Intervention: Ipilimumab (overall treatment)
Number of subjects: 42
Study 29145543 — intervention group
Group type: EXPERIMENTAL
Intervention: Ipilimumab (immune analyses)
Number of subjects: 42
Study 29145543 — intervention group
Group type: EXPERIMENTAL
Intervention: Ipilimumab (immune changes)
Number of subjects: 42
Study 27871308 — intervention group
Group type: EXPERIMENTAL
Intervention: Telephone information delivery
Number of subjects: 0
Study 27871308 — intervention group
Group type: COMPARATOR
Intervention: Face-to-face consultation
Number of subjects: 0
Study 24384905 — intervention group
Group type: EXPERIMENTAL
Intervention: Structured advance care planning (ACP) session by a trained nurse
Number of subjects: 0
Study 24384905 — intervention group
Group type: COMPARATOR
Intervention: Control group (no structured ACP session)
Number of subjects: 0
Study 24384905 — intervention group
Group type: EXPERIMENTAL
Intervention: Structured ACP session
Number of subjects: 0
Study 22974314 — intervention group
Group type: EXPERIMENTAL
Intervention: Structured multi-disciplinary team intervention including a gerontology nurse specialist (GNS) intervention, baseline facility needs assessment, quality indicator benchmarking, staff education programme, and care coordination.
Number of subjects: 1700
Study 22974314 — intervention group
Group type: COMPARATOR
Intervention: Control group (not explicitly detailed in the abstract).
Number of subjects: 1700
Study 21077506 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.625 mg conjugated equine estrogen
Number of subjects: 3
Study 21077506 — intervention group
Group type: EXPERIMENTAL
Intervention: 3.9 mg transdermal 17beta‐estradiol patch
Number of subjects: 3
Study 21077506 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 3
Study 18675097 — intervention group
Group type: EXPERIMENTAL
Intervention: Everolimus (EVL)
Number of subjects: 40
Study 18675097 — intervention group
Group type: COMPARATOR
Intervention: Cyclosporine (CsA)
Number of subjects: 40
Study 16004014 — intervention group
Group type: EXPERIMENTAL
Intervention: Botox injections into one half of the chin
Number of subjects: 20
Study 16004014 — intervention group
Group type: COMPARATOR
Intervention: Placebo (saline) injections into the other half of the chin
Number of subjects: 20
Study 16004014 — intervention group
Group type: EXPERIMENTAL
Intervention: Botox injections
Number of subjects: 20
Study 16004014 — intervention group
Group type: COMPARATOR
Intervention: Placebo (saline) injections
Number of subjects: 20
Study 12857521 — intervention group
Group type: EXPERIMENTAL
Intervention: Shen-Fu (SF) injection (0.5 ml/kg at the beginning of surgery, followed by continuous infusion of 100 ml SF (1.0 ml/kg) diluted in saline at 0.004 ml x Kg(‐1) x min(‐1))
Number of subjects: 38
Study 12857521 — intervention group
Group type: COMPARATOR
Intervention: Normal saline (control group)
Number of subjects: 38
Study 12857521 — intervention group
Group type: EXPERIMENTAL
Intervention: Shen-Fu (SF) injection
Number of subjects: 38
Study 10573502 — intervention group
Group type: EXPERIMENTAL
Intervention: Anterolateral paddle position (group AL)
Number of subjects: 301
Study 10573502 — intervention group
Group type: COMPARATOR
Intervention: Anteroposterior paddle position (group AP)
Number of subjects: 301
Study 8948561 — intervention group
Group type: EXPERIMENTAL
Intervention: Daily screening of respiratory function followed by two-hour trials of spontaneous breathing in appropriate patients.
Number of subjects: 300
Study 8948561 — intervention group
Group type: COMPARATOR
Intervention: Daily screening without further intervention (control group).
Number of subjects: 300
Study 2008181 — intervention group
Group type: EXPERIMENTAL
Intervention: 300 mg of pentamidine isethionate every 28 days by inhaler
Number of subjects: 223
Study 2008181 — intervention group
Group type: COMPARATOR
Intervention: 300 mg of sodium isethionate every 28 days by inhaler (placebo)
Number of subjects: 223
Study 6796618 — intervention group
Group type: EXPERIMENTAL
Intervention: Glutaraldehyde-modified, tyrosine-adsorbed ragweed extract (GTR)
Number of subjects: 100
Study 6796618 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 100
Study 30303611 — intervention group
Group type: EXPERIMENTAL
Intervention: Phrenic nerve stimulation
Number of subjects: 96
Study 30303611 — intervention group
Group type: COMPARATOR
Intervention: Control group (former control patients)
Number of subjects: 96
Study 27617380 — intervention group
Group type: EXPERIMENTAL
Intervention: Tell-show-do method plus visual schedule system
Number of subjects: 14